Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1946240 | 0.85 | KMT2A (0.61) | KMT2AALDH1A1CYP3A4MEN1SMN1; SMN2 | |
| SCHEMBL1945172 | 0.82 | KMT2A (0.58) | KMT2AALDH1A1CYP3A4MEN1SMN1; SMN2 | |
| SCHEMBL1713239 | 0.80 | KMT2A (0.56) | KMT2AALDH1A1CYP3A4MEN1SMN1; SMN2 | |
| SCHEMBL2328939 | 0.80 | ALDH1A1 (0.59) | KMT2AALDH1A1CYP3A4MEN1SMN1; SMN2 | |
| SCHEMBL1948407 | 0.79 | ALDH1A1 (0.56) | KMT2AALDH1A1CYP3A4MEN1SMN1; SMN2 | |
| SCHEMBL5421938 | 0.79 | ALDH1A1 (0.54) | KMT2AALDH1A1CYP3A4MEN1SMN1; SMN2 | |
| SCHEMBL10729879 | 0.79 | ALDH1A1 (0.50) | KMT2AALDH1A1CYP3A4MEN1SMN1; SMN2 | |
| SCHEMBL1319862 | 0.79 | KMT2A (0.55) | KMT2AALDH1A1CYP3A4MEN1SMN1; SMN2 | |
| SCHEMBL7179000 | 0.79 | KMT2A (0.55) | KMT2AALDH1A1CYP3A4MEN1SMN1; SMN2 | |
| SCHEMBL4809763 | 0.79 | KMT2A (0.55) | KMT2AALDH1A1CYP3A4MEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-3894410-B1 | SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2023-10-11 | — | — | EP | disclosed |
| EP-3894409-B1 | SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2023-08-23 | — | — | EP | disclosed |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20220177479-A1 | NOVEL SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-06-09 | — | — | US | disclosed |
| CN-110997675-B | Novel substituted xanthine derivatives | 勃林格殷格翰国际公司 | 2022-06-07 | — | — | CN | disclosed |
| EP-3652176-B1 | SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2021-12-15 | — | — | EP | disclosed |
| WO-2006044610-A1 | METHOD OF PREVENTING AND TREATING AIRWAY REMODELING AND PULMONARY INFLAMMATION USING A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060058322-A1 | Method of wound healing using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2006-03-16 | — | — | US | disclosed |
| US-20040176399-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2004-09-09 | — | — | US | disclosed |
| US-6177437-B1 | VIRICIDES | UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER | 2001-01-23 | — | — | US | disclosed |
| EP-0378850-B1 | Substituted pyrido(2,3-d) pyrimidines | BAYER AG (DE) | 1994-04-06 | — | — | EP | disclosed |
| US-5145959-A | Enzyme inhibitors; antilipemic agents; treatment of atherosclerosis | BAYER AKTIENGESELLSCHAFT (DE) | 1992-09-08 | — | — | US | disclosed |
| US-5075311-A | Anticholesterol agents | BAYER AKTIENGESELLSCHAFT (DE) | 1991-12-24 | — | — | US | disclosed |
| EP-0378850-A2 | Substituted pyrido(2,3-d) pyrimidines | BAYER AG (DE) | 1990-07-25 | — | — | EP | disclosed |
| CN-1043938-A | The pyrido of new replacement [2,3-d] pyrimidines | BAYER AG (DE) | 1990-07-18 | — | — | CN | disclosed |
| EP-0065934-A1 | Chlorine-containing thermoplastic polymers stabilised with amino uracils | CIBA-GEIGY AG (CH) | 1982-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | MTHFD2, MTHFD1, NUDT15 | KMT2A 924/4885ALDH1A1 260/4885CYP3A4 830/4885 |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | MTHFD2, MTHFD1, NUDT15 | KMT2A 924/4885ALDH1A1 260/4885CYP3A4 830/4885 |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | MTHFD2, MTHFD1, NUDT15 | KMT2A 924/4885ALDH1A1 260/4885CYP3A4 830/4885 |
| US-20040176399-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | KMT2A 2738/4885ALDH1A1 779/4885CYP3A4 925/4885 |
| US-20060058322-A1 | Method of wound healing using A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | KMT2A 3178/4885ALDH1A1 470/4885CYP3A4 3096/4885 |
| US-20220177479-A1 | NOVEL SUBSTITUTED XANTHINE DERIVATIVES | TRPC5, TRPC4, TRPM5 | KMT2A 4516/4885ALDH1A1 962/4885CYP3A4 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.